Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation

PURPOSE: Dolutegravir (DTG) is primarily metabolized by UGT1A1 with CYP3A as a minor route. Carbamazepine (CBZ) is a potent inducer of these enzymes; thus, the effect of oral extended-release CBZ on DTG pharmacokinetics (PK) was evaluated to provide dose recommendation when co-administered. METHODS:...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Clin Pharmacol
Päätekijät: Song, Ivy, Weller, Steve, Patel, Juhin, Borland, Julie, Wynne, Brian, Choukour, Mike, Jerva, Fred, Piscitelli, Stephen
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Berlin Heidelberg 2016
Aiheet:
Clinical Trial
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4865535/
https://ncbi.nlm.nih.gov/pubmed/26898568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-016-2020-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia